ASCO Annual Meeting

Patients Willing to Pay Out of Pocket for Genetic Testing to Assess Colorectal Cancer Risk

Audrey Andrews

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Chicago, IL—In a cohort of patients at risk for colorectal cancer (CRC), the majority were willing to pay some out-of-pocket (OOP) expenses for genetic testing, Fox Chase Cancer Center researchers reported in a poster that was presented at the 2012 American Society of Clinical Oncology (ASCO) meeting and earned an ASCO Merit Award.

“These participants are fearful of a positive result and anticipate benefits afforded by genetic testing in controlling cancer risk,” said Jennifer M. Matro, MD, a medical oncology fellow at Fox Chase in Philadelphia.

[ Read More ]

High OOP Costs for Medicare Patients with Cancer

Mark Knight

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Chicago, IL—Older patients with cancer and Medicare coverage often incur greater out-of-pocket (OOP) expenses compared with their counterparts without cancer. Factors contributing to the greater expenses for those patients include comorbidities and lack of supplemental insurance. As a result, older patients often hesitate to seek treatment for cancer because of financial concerns, according to a study presented by Amy J. [ Read More ]

Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy

Wayne Kuznar

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Approximately 1 in 5 patients with cancer who are undergoing radiotherapy as part of their treatment can count on unexpected hospital stays—adding an economic and clinical burden on the patient and on the healthcare system, according to an analysis by Nabeel H. Arastu, BS, and colleagues at the Brody School of Medicine at East Carolina University, Greenville, NC, which was presented at the 2012 ASCO meeting.

[ Read More ]

New Androgen Receptor–Signaling Inhibitor Extends Survival, Improves QOL in Advanced Prostate Cancer

Mark Knight

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Chicago, IL—The novel androgen receptor–signaling inhibitor enzalutamide, also known as MDV3100, significantly prolonged overall survival (OS), slowed disease progression, and improved quality-of-life (QOL) measures in men with castration-resistant prostate cancer after docetaxel failure, according to results from a large phase 3 clinical trial.

[ Read More ]

BRAF and MEK Inhibitors Make News at ASCO

Audrey Andrews

June 2012, Vol 3, No 4 - ASCO Annual Meeting

Chicago, IL—At the 2012 American Society of Clinical Oncology meeting, attendees flocked to sessions on the treatment of melanoma to hear about the next generation of agents that are building on the success achieved with the BRAF inhibitor vemurafenib (Zelboraf), and the immunotherapy drug ipilimumab (Yervoy), which have added new treatment options where, not long ago, none existed.

[ Read More ]

Abiraterone Merits Consideration as New Standard Before Chemotherapy for Treatment of Prostate Cancer

June 2012, Vol 3, No 4 - ASCO Annual Meeting

Chicago, IL—Abiraterone acetate (Zytiga) delays disease progression when used with prednisone before chemotherapy in men with metastatic castration-resistant prostate cancer, said Charles J. Ryan, MD, Associate Professor of Clinical Med icine, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, who reported a planned interim analysis of a phase 3 study at the 2012 meeting of the American Society of Clinical Oncology.

[ Read More ]

Biomarker Identifies Patients with Rare Brain Tumors Who Have a Survival Benefit from Chemotherapy Plus Radiation

Phoebe Starr

June 2012, Vol 3, No 4 - ASCO Annual Meeting

Chicago, IL—Patients with the relatively rare brain tumor anaplastic oligodendroglioma who were treated with adjuvant chemotherapy after standard radiation therapy had improved survival compared with radiation alone, especially if they had codeletion of chromosomes 1p/19q, according to long-term follow-up of the EORTC (European Organisation for Research and Treatment of Cancer) 2651 study reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

[ Read More ]